Focus Stocks
AstraZeneca US Broadens Income Eligibility for Prescription Savings Programs
Published on Wednesday, 08 February 2012 09:08 Written by TradersHuddle Staff
WILMINGTON, Del.-( Business Wire )-AstraZeneca (NYSE:AZN) announced today that it broadened the income eligibility for its AZ&Me™ Prescription Savings programs to enable more people to qualify for free medicines.
The new annual household income eligibility levels are $35,000 for individuals, $48,000 for couples, $60,000 for a family of three and $70,000 for a family of four.
Those with an annual household income that falls within the new income eligibility guidelines may receive AstraZeneca medicines for free if they meet all program criteria.
"We made this change to keep pace with the increased cost of living for patients and to ensure they have access to medicines they need,” said Jennifer McGovern, Director, AZ&Me Prescription Savings Programs.
Previously, AstraZeneca provided prescription savings benefits to qualified patients with a total yearly income of $30,000 for individuals, $40,000 for couples, $50,000 for a family of three and $60,000 for a family of four.
In 2010, AstraZeneca also expanded its prescription savings program to provide assistance to those with extenuating circumstances such as those who recently lost their jobs, had their incomes reduced, experienced a change in marital status or had a change in family size. Those who submit documentation showing the change in status may qualify for the program.
AstraZeneca has offered prescription savings programs for 34 years and offers one of the industry’s most generous programs. The company will continue to make program enhancements that better serve patients and the advocates who help them.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
Related Articles
- AstraZeneca near Support
- Is AstraZeneca Breaking Down?
- SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows Similar Safety Profile When Compared to Budesonide Monotherapy in African-American Patients with Asthma
- LUNAR Examines Cholesterol-Lowering Effects of CRESTOR® (rosuvastatin calcium) Compared with Atorvastatin in Patients with Acute Coronary Syndrome
- Up/Downgrades
- Up/Downgrades
- Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and Sotheby's Released By InvestorsObserver
- AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease
- Ardea Biosciences, Inc. (RDEA) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition by AstraZeneca PLC
- AstraZeneca Launches DUTOPROL™ (metoprolol succinate extended release/hydrochlorothiazide) Tablets for High Blood Pressure in U.S.
Related Partner Headlines
- AstraZeneca PLC (AZN): Today's Featured Health Care Winner - TheStreet.com
- AstraZeneca LUNAR Examines Cholesterol-Lowering Effects of CRESTOR Compared with Atorvastatin in Patients with Acute Coronary Syndrome - Benzinga
- Benzinga's Top Upgrades - Benzinga
- AstraZeneca PLC (AZN): Today's Featured Drugs Loser - TheStreet.com
- Rupert Murdoch in Second Day of Testimony: Hot Trends - TheStreet.com
- AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends - TheStreet.com
- Thursday's Top 10 Articles, Videos on TheStreet - TheStreet.com
- 10 Dividend Stocks Still Paying Outsized Yields - TheStreet.com
- AstraZeneca Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX Tablets to Patients for Only $40 Per Month - Benzinga
- Notable Call Options Activity in AstraZeneca - Benzinga
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Cramer's 'Mad Money' Recap: Big Government Not Protecting the Little Guys - TheStreet.com -
The Global Retrenchment Accelerates - TheStreet.com -
Bain Capital Sent 0,000-Plus to Obama and Dems in 2008 - TheStreet.com -
Market Preview: Low-Grade Uncertainty - TheStreet.com -
The EPA's Dangerous Game - TheStreet.com -
Sticking with the Preferred Plan - TheStreet.com -
Infoblox Posts Blowout Earnings; Shares Rise - TheStreet.com -
Salesforce.com Inc. (CRM): Today's Featured Computer Software & Services Loser - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
SCVBank Elects Scott K. Rushing as New Chairman -
Heritage Oaks Bancorp to Pay Trust Preferred Interest and Accumulated TARP Dividends -
Law Office of Brodsky & Smith, LLC Announces Investigation of Ariba, Inc. -
Following Its Record 73% Jump FY 2011 Revenue, Privately-Held Milton Security Group Reports Repeat Double-Digit Sales Growth for First Quarter 2012 -
Diamond Value Management strategy and corporate turnaround leverages Rockwell repositioning -
Verizon Singapore Lauded for Its Sustainability Efforts -
Photo Release -- Cars For a Living: The World's First High-Octane Business Podcast -
Internal Fixation Systems, Inc. Enters Into $7.5M Equity Purchase Agreement With Hyde Park Advisors, LLC, an Affiliate of Institutional Investor Central Park Financial









